Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ebronucimab Phase 3 in Primary Hypercholesterolemia and Mixed Hyperlipidemia
NCT05255094Phase 3Completed
- Sponsor
- Akeso, Inc.
- Start
- Nov 2021
- Primary completion
- Jun 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ebronucimab in hypercholesterolemia and mixed hyperlipidemia (4 arms), sponsored by Akeso, Inc. Primary endpoint: Percentage change from baseline of serum LDL-C level at 12 weeks. Started Nov 2021; status: completed.
02
Drugs
ebronucimab
03
Conditions
hypercholesterolemiamixed hyperlipidemia
Beyond the preview
Go deeper on NCT05255094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05255094.